Last week, readers were most interested in a story about BD's plan to separate its Biosciences and Diagnostics Solutions business by the end of 2026.
The diagnostics startup is developing a testing platform that uses digital imaging and signal processing for pathogen identification and susceptibility determination.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback